Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure TEL AVIV, Israel and MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today presented 30-day results from the C-GUARDIANS […]
Peripheral/Endo
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23
LAS VEGAS, Oct. 31, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four Late-Breaking Clinical Trial sessions at the…
Endovascular Engineering, Inc. Announces Positive Initial Results in ENGULF Study for Hēlo™ Thrombectomy System
ENGULF Study utilizing next generation technology in targeting pulmonary embolism MENLO PARK, Calif., Oct. 31, 2023 /PRNewswire/ — Endovascular Engineering (“E2”), a mission driven, venture-backed, medical device company focused on the development and deployment of next generation clot…
Late-Breaking Clinical Trial Results Announced at The VEINS 2023
LAS VEGAS, Oct. 30, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the Late-Breaking Clinical Trials session at The VEINS conference,…
Cardio Flow Announces Completion of First Commercial Cases of Innovative FreedomFlow Orbital Atherectomy Platform—and Appointment of Chief Operating Officer
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardio Flow, Inc., a privately held commercial-stage medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), is pleased to announce the successful completion of its first commercial cases for its FreedomFlow® Orbital Atherectomy Platform following FDA clearance in late September. First Commercial Case Performed by the Cardiovascular Institute of the South (CIS) Cardio Flow announced the successful completion
Evident Vascular Announces Scientific Advisory Board and New Board Member
SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors. “It is our privilege to have this esteemed group of clinical experts on our Scientific Advisory Board. Their collective expertise and experience innovating new periph
Sirtex Medical Announces Commercial Availability of New LAVA® Liquid Embolic System
Sirtex unveils first-of-its-kind product to treat peripheral vascular hemorrhage WOBURN, Mass., Oct. 27, 2023 /PRNewswire/ — Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, announced today the commercial availability of the LAVA® Liquid Embolic…
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ — Data from the REAL-PE study was presented today at Transcatheter Cardiovascular Therapeutics…
Endologix’s DETOUR™ System Earns Spot in Local and National Award Forums; Nominated for Prix Galien USA’s Best Medical Technology
IRVINE, Calif.–(BUSINESS WIRE)– #DETOURSystem–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, proudly announces recent awards and nominations for its groundbreaking DETOUR System. Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral artery, by using conduits routed th
Frontier Bio Leads Medical Innovation with “Lab-Grown” Blood Vessel Technology for Replacing Animal Testing
SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ — Frontier Bio Corporation has unveiled a transformative method designed to fabricate living human blood vessels, setting the stage for a radical shift in medical device testing. At present, vascular medical devices must be assessed for safety…
Recent
Transverse Medical Inc. Announces Completion of First Series of Patients in Feasibility Clinical Study at Victorian Heart Hospital, Melbourne, Australia, Using Point-Guard Cerebral Embolic Protection.
The Future of AI & Electrophysiology Takes Center Stage at Heart Rhythm 2025 with Vektor Medical
CathVision to Exhibit the Latest Advancements in Electrophysiology at Heart Rhythm Society 2025 in San Diego
Popular
- No commented posts yet